US2024041895A1PendingUtilityA1
Combination therapy for treating cancer
Est. expiryMar 31, 2037(~10.7 yrs left)· nominal 20-yr term from priority
A61K 31/5377A61P 35/00A61K 31/282A61K 31/4184A61K 31/436A61K 31/4406A61K 31/4745A61K 31/475A61K 31/506A61K 31/519A61K 31/55A61K 31/704A61K 31/7048A61K 31/7068A61K 38/15A61N 5/10A61K 31/4412A61K 31/445A61K 31/496
71
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure relates to methods of a malignant rhabdoid tumor (MRT), a rhabdoid tumor of the kidney (RTK), an atypical teratoid/rhabdoid tumor (AT/RT), an epithelioid malignant peripheral nerve sheath tumor, a myoepithelial carcinoma, and/or a renal medullary carcinoma by using an EZH2 inhibitor in combination with one or more additional treatment modalities.
Claims
exact text as granted — not AI-modified1 . A method for treating a malignant rhabdoid tumor (MRT) or an atypical teratoid/rhabdoid tumor (AT/RT) comprising administering to a subject:
(a)
(tazemetostat), or a pharmaceutically acceptable salt thereof, and
(b) vincristine, topotecan, entinostat, romidepsin, palbociclib, or trametinib.
2 - 8 . (canceled)
9 . The method of claim 1 , wherein the vincristine, topotecan, entinostat, romidepsin, palbociclib, or trametinib is administered prior to the tazemetostat.
10 . The method of claim 1 , wherein the tazemetostat is administered prior to the vincristine, topotecan, entinostat, romidepsin, palbociclib, or trametinib.
11 - 13 . (canceled)
14 . A method for treating a malignant rhabdoid tumor (MRT) or an atypical teratoid/rhabdoid tumor (AT/RT), the method comprising sensitizing a subject, wherein sensitizing comprises administering to the subject:
(tazemetostat), or a pharmaceutically acceptable salt thereof, and
(b) vincristine, topotecan, entinostat, romidepsin, palbociclib, or trametinib.
15 - 30 . (canceled)
31 . A method of inhibiting or decreasing growth, viability, survival, or proliferation of a cancer cell comprising (1) contacting the cell with (a) an effective amount of EZH2 inhibitor, and (b) one or more second agents, or (2) contacting the cell with an effective amount of EZH2 inhibitor and exposing the cell to a radiation, wherein the cancer cell is an atypical teratoid rhabdoid tumor cell or a malignant rhabdoid tumor cell.
32 - 39 . (canceled)
40 . The method of claim 1 , wherein the tazemetostat is administered orally.
41 . (canceled)
42 . The method of claim 1 , wherein the subject is a human being.
43 . (canceled)
44 . The method of claim 1 , wherein the tazemetostat is administered to the subject at a dose of about 100 mg to about 3200 mg daily.
45 - 46 . (canceled)
47 . The method of claim 44 , wherein the tazemetostat is administered to the subject at a dose of 800 mg BID.
48 .- 91 . (canceled)
92 . The method of claim 1 , comprising administering entinostat or romidepsin to the subject.
93 . The method of claim 92 , comprising administering entinostat to the subject.
94 . The method of claim 92 , comprising administering romidepsin to the subject.
95 . The method of claim 1 , wherein the method is for treating an MRT.
96 . The method of claim 1 , wherein the method is for treating an AT/RT.
97 . The method of claim 92 , wherein the method is for treating an MRT.
98 . The method of claim 92 , wherein the method is for treating an AT/RT
99 . The method of claim 1 , comprising administering vincristine to the subject.
100 . The method of claim 1 , comprising administering topotecan to the subject.
101 . The method of claim 1 , comprising administering palbociclib to the subject.
102 . The method of claim 1 , comprising administering trametinib to the subject.Join the waitlist — get patent alerts
Track US2024041895A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.